wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677
Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677
Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
P2860
Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42682716-84ACDA53-890D-4133-B72E-3F7E01622677
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9db9298d9345bdb421d38074678ca0b01014b8bd
P2860
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.